Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study

References

• World Health Organization. Hepititis C Fact Sheet. Geneva, Switzerland: World Health Organization, 2015. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed October 9, 2015
   Google Scholar
• McCaw R, Moaven, L, Locarnini, SA. Hepatitis C virus genotypes in Australia. J Viral Hepatitis 1997;4:351-7
   PubMed Web of Science ®Google Scholar
• Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014;60:37-45
   PubMed Web of Science ®Google Scholar
• Gidding H, Law M, Amin J, et al. Predictors of deferral of treatment for hepatitis C infection in Australian clinics. MJA 2011;194:398-402
   PubMed Web of Science ®Google Scholar
• The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2015. Sydney: Kirby Institute, The Universitiy of New South Wales, 2015
   Google Scholar
• National Centre in HIV Epidemiology and Clinical Research. Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia 2010. Sydney, NSW: National Centre in HIV Epidemiology and Clinical Research, 2010
   Google Scholar
• Visconti AJ, Doyle JS, Weir A, et al. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. J Gastroenterol Hepatol 2013;28:707-16
   PubMed Web of Science ®Google Scholar
• Warren E, Wright A, Jones B. Cost-effectiveness of telaprevir in patients with genotype 1 hepatitis C in Australia. Value Health 2014;17:792-800
   PubMed Web of Science ®Google Scholar
• Cure S, Bianic F, Gavart S, et al. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. J Med Econ 2014;17:65-76
   PubMedGoogle Scholar
• Gellad ZF, Muir AJ, McHutchison JG, et al. Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. Value Health 2012;15:876-86
   PubMed Web of Science ®Google Scholar
• Turnes J, Romero-Gomez M, Planas R, et al. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. Gastroenterol Hepatol 2013;36:555-64
   PubMed Web of Science ®Google Scholar
• McEwan P, Ward T, Webster S, et al. Estimating the long-term clinical and economic outcomes of daclatasvir plus asunaprevir in difficult-to-treat Japanese patients chronically infected with hepatitis C genotype 1b. ViHRI 2014;3C:136-45
   Google Scholar
• Elbasha EH, Chhatwal J, Ferrante SA, et al. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. Appl Health Econ Health Policy 2013;11:65-78
   PubMedGoogle Scholar
• McEwan P, Kim R, Yuan Y. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Policy 2013;11:53-63
   PubMedGoogle Scholar
• Obach D, Deuffic-Burban S, Esmat G, et al. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. Clin Infect Dis 2014;58:1064-71
   PubMed Web of Science ®Google Scholar
• Liu S, Cipriano LE, Holodniy M, et al. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012;156:279-90
   PubMed Web of Science ®Google Scholar
• Saab S, Gordon SC, Park H et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014;40:657-75
   PubMed Web of Science ®Google Scholar
• Chan K, Lai MN, Groessl EJ, et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol 2013;11:1503-10
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Park H, Saab S, et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2015;41:544-63
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban S, Schwarzinger M, Obach D, et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). J Hepatol 2014;61:7-14
   PubMed Web of Science ®Google Scholar
• Hartwell D, Jones J, Baxter L, et al. Shortened peginterferon and ribavirin treatment for chronic hepatitis C. Int J Technol Assess Health Care 2012;28:398-406
   PubMed Web of Science ®Google Scholar
• McAdam-Marx C, McGarry LJ, Hane CA, et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011;17:531-46
   PubMed Web of Science ®Google Scholar
• Wright M, Grieve R, Roberts J, et al; Investigators UKMHCT. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10:1-113, iii
   Web of Science ®Google Scholar
• Schwarzinger M, Deuffic-Burban S, Mallet V, et al. Lifetime costs attributable to chronic hepatitis C from the French healthcare perspective (ANRS No 12188). J Hepatol 2013;58:S21-S2
   Web of Science ®Google Scholar
• Rein DB, Borton J, Liffmann DK, et al. The burden of hepatitis C to the United States Medicare system in 2009: descriptive and economic characteristics. Hepatology 2016;63:1135-44.
   PubMed Web of Science ®Google Scholar
• Department of Health and Ageing. Manual of Resource Items and their Associated Costs. Canberra, Australia: Commonwealth Department of Health and Ageing, 2009
   Google Scholar
• Department of Health. MBS Online 1 July 2015. Canberra, Australia: Department of Health, 2015. http://www.mbsonline.gov.au/. Accessed August 5, 2015
   Google Scholar
• Independent Hospital Pricing Authority. National Hospital Cost Data Collection Australian Public Hospitals Cost Report 2012-2013, Round 17. Appendix B Cost Weights (Actual) for AR-DRG version 6.0x, Round 17 (2012-13). Darlinghurst, NSW, Australia: Independent Hospital Pricing Authority, 2015. http://www.ihpa.gov.au/internet/ihpa/publishing.nsf/Content/nhcdc-lp. Accessed 5 August, 2015
   Google Scholar
• National Centre in HIV Epidemiology and Clinical Research. Australian Chronic Hepatitis C Observational Study (ACHOS) Report No. 1 March 2010. Sydney: The University of New South Wales, 2010
   Google Scholar
• LaMori J, Tandon N, Laliberte F, et al. Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C. J Med Econ 2016;19:364-73
   PubMed Web of Science ®Google Scholar
• Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust 2016;204:268-72
   PubMed Web of Science ®Google Scholar